![Ori Biotech](/img/default-banner.jpg)
- 32
- 3 086
Ori Biotech
Registrace 30. 03. 2021
Ori Biotech is an innovator in Cell and Gene Therapy manufacturing, delivering scalable solutions to address the critical needs of therapeutics developers.
Carl Schoellhammer: viability is the crucial third pillar in CGT
In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy in cell and gene therapies (CGTs).
Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.
Learn more about Carl: www.linkedin.com/in/carl-schoellhammer/
Schoellhammer highlights the need for scalable and decentralized manufacturing approaches to ensure the commercial viability of these advanced therapies, as well as the challenges of maintaining consistent quality in personalized medicines, and the role of enabling technologies in addressing these hurdles.
Learn more about Carl: www.linkedin.com/in/carl-schoellhammer/
zhlédnutí: 33
Video
Anshul Mangal: Unlocking scale, automation, digitalization and standardization in CGT
zhlédnutí 66Před 2 měsíci
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic planning, and the role of digitalization in improving efficiency and reducing costs. Together they also highlight the potential of distributed manufacturing and the evolution of regulatory standard...
Omkar Kawalekar: technology will unlock scalability and patient access
zhlédnutí 91Před 3 měsíci
In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufacturing challenges and developing advanced therapies at scale. Their conversation covers key industry hurdles like supply chain optimization and the strategic planning necessary for bringing innovative ...
Joe DePinto: bridging growth and accessibility within CGTs
zhlédnutí 107Před 3 měsíci
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therapy manufacturing and supply chains. Together they also highlight the importance of collaborative partnerships and digital innovations to enhance access and streamline processes within the CGT sector....
Matthew Hewitt: scalability is a collective problem
zhlédnutí 60Před 5 měsíci
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to discuss why industry collaboration is needed to experience the true impact of advanced therapies and develop them at a commercial scale. Together they also highlight the role of technology in closing,...
Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility
zhlédnutí 127Před 6 měsíci
In this episode of the Ori Spotlight Podcast, Jason C. Foster hosts Jeff Holder and Adam Siebert from LEK Consulting, offering an in-depth exploration of the evolving cell and gene therapy (CGT) industry. LEK Consulting, a global leader in strategic advisory, aims to address the critical challenges of scalability and commercial viability within the CGT sector. Jeff and Adam, with their extensiv...
Jim Faulkner: unaffordable therapy success is worse than failure...
zhlédnutí 123Před 6 měsíci
In this episode of Ori Spotlight Podcast, we welcome Jim Faulkner, PhD, Independent Consultant at JDB BioConsulting and former SVP of Product Delivery at Autolus. Jim brings a wealth of experience from his remarkable career in biopharmaceutical development and his journey in the industry is marked by significant contributions, particularly in pioneering cell therapy at GSK. The episode offers a...
Sanjay Srivastava: are CGTs developing into a commercial dead-end?
zhlédnutí 86Před 7 měsíci
In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies. Sanjay and Jason C. Foster delve into the critical challenges f...
Jason C. Foster interviews Bruce Thompson at ARM's Meeting on the Mesa
zhlédnutí 127Před 8 měsíci
Jason C. Foster interviews Bruce Thompson at ARM's Meeting on the Mesa
Jason C. Foster interviews Matthew Hewitt at ARM's Meeting on the Mesa
zhlédnutí 111Před 8 měsíci
Jason C. Foster interviews Matthew Hewitt at ARM's Meeting on the Mesa
Jason C. Foster interviews Jason Bock at ARM's Meeting on the Mesa
zhlédnutí 85Před 8 měsíci
Jason C. Foster interviews Jason Bock at ARM's Meeting on the Mesa
2023 Data Release: Jason C. Foster at the Cell & Gene Meeting on the Mesa
zhlédnutí 737Před 9 měsíci
2023 Data Release: Jason C. Foster at the Cell & Gene Meeting on the Mesa
Tim Hunt: leading CGT with education and community
zhlédnutí 52Před rokem
We’re joined by Tim Hunt, CEO of Alliance for Regenerative Medicine (ARM). As an international advocacy organization, ARM is a global voice within the cell and gene therapy sector. They champion the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society as well as facilitating influential exchanges on policies and practices, and advances in nar...
Vered Caplan: why yesterday’s thinking is not going to solve today’s problems
zhlédnutí 180Před rokem
We’re joined by Vered Caplan, CEO of Orgenesis, as she shares her insights into the cell and gene therapy sector. With a background in engineering and business, Vered found her passion in the cell and gene therapy industry. She founded Orgenesis with a mission to bring innovative therapies to patients, by leveraging cutting-edge science to create a more efficient, scalable, and affordable pathw...
Daniel Gibson: improving patient access to cell therapies
zhlédnutí 56Před rokem
Daniel Gibson: improving patient access to cell therapies
Dr Betty Woo: Why it's important to take calculated risks early in your career
zhlédnutí 44Před rokem
Dr Betty Woo: Why it's important to take calculated risks early in your career
Jason Bock - Cell Manufacturing Therapy Center (CTMC)
zhlédnutí 62Před rokem
Jason Bock - Cell Manufacturing Therapy Center (CTMC)
John Lee: “Cellicon Valley” accelerates development and manufacturing of innovative CGTs
zhlédnutí 102Před rokem
John Lee: “Cellicon Valley” accelerates development and manufacturing of innovative CGTs
The Whitehead and Jones Families - Patient Advocates
zhlédnutí 35Před rokem
The Whitehead and Jones Families - Patient Advocates
Amy Kappen: connecting CAR-T families with The Best Day Ever Foundation
zhlédnutí 108Před rokem
Amy Kappen: connecting CAR-T families with The Best Day Ever Foundation
Isabelle Rivière - Memorial Sloan-Kettering Cancer Center (MSKCC)
zhlédnutí 45Před rokem
Isabelle Rivière - Memorial Sloan-Kettering Cancer Center (MSKCC)
William Raimes, Head of Process Development
zhlédnutí 67Před rokem
William Raimes, Head of Process Development
Keara Traylor, Associate Director, Technical Operations
zhlédnutí 47Před rokem
Keara Traylor, Associate Director, Technical Operations
Mark Varley, Associate Director, Hardware
zhlédnutí 45Před rokem
Mark Varley, Associate Director, Hardware